Publication | Closed Access

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Second-line TreatmentSalvage ChemotherapyInterim AnalysisLymphoid NeoplasiaTransplantationMarrow TransplantationOncologyCell Replacement TherapySurgeryRadiation OncologyMedicineCell Transplantation